Status:
RECRUITING
Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis
Lead Sponsor:
Tanta University
Collaborating Sponsors:
Prof. Sahar Kamal Hegazy, Professor of Clinical Pharmacy, Faculty of Pharmacy - Tanta University
Dr. Mustafa Adel Mustafa Elmenawy Lecturer of Rheumatology and Rehabilitation, Faculty of Medicine - El-Azhar University - Damietta
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Rheumatoid arthritis (RA) is a long-term inflammatory condition that leads to gradual damage of joints lined by synovial membranes, along with various potential effects outside of the joints. While RA...
Eligibility Criteria
Inclusion
- Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) \[9\] i.e., 28 joints disease activity score (DAS 28) \>2.6.
- Patients receiving the conventional DMARDs.
- Both sexes.
- Age range between 18and 70 years old
Exclusion
- Patients with retinal or cerebral hemorrhage.
- Patients with renal and hepatic dysfunction.
- Patients with hypersensitivity to study medications.
- Pregnant and lactating females.
- Patients receiving biological or synthetic DMARDs
Key Trial Info
Start Date :
June 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06998628
Start Date
June 2 2025
End Date
September 30 2026
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Al-Azhar University
Damietta, Damietta Governorate, Egypt, 34511